Cytomegalovirus antigens
US10364273B2 · kind B2 · utility
0Cited by
1References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 7, 2015 |
| Grant date | Jul 30, 2019 |
| Priority date | — |
| Expiry date | Dec 7, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/16134
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention generally relates to recombinant human cytomegalovirus (CMV) gB proteins and immunogenic fragments thereof, which do not comprise a transmembrane (TM) domain; and comprise one or more mutations that reduce the aggregation between the monomeric trimers of gB, and/or adhesion of the monomeric trimer of gB to the host cell.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.